Cartalax

The cartalax peptide is a three-amino-acid bioregulator marketed for cartilage and joint repair, but no human trial has shown those benefits. The strongest verified evidence is a cell-culture gene-expression study, not repaired cartilage, less pain, or better movement. Cartalax is not FDA-approved, and its human dose and safety profile remain unknown.

Key facts

• What it is: the synthetic Ala-Glu-Asp tripeptide listed by PubChem as Cartalax
• Studied for: aging-related gene expression in cultured cells
• Evidence tier: in-vitro; no human trial
• U.S. status (July 2026): not FDA-approved; marketed as research use only
• Cartalax peptide dosage: no validated human dose
• Main risk: human effects and product identity are both uncertain
• Sport: not named individually by WADA; its S0 non-approved-substances rule still warrants caution

What is the cartalax peptide?

The cartalax peptide is the synthetic tripeptide Ala-Glu-Asp, abbreviated AED, in the authoritative chemical record used here. PubChem lists Cartalax as a synonym for alanyl-glutamyl-aspartic acid, with three amino acids, formula C12H19N3O8, molecular weight 333.29 g/mol, and CID 87815447.

That identity needed checking because current search results disagree. Some pages call Cartalax AED; others publish four-amino-acid versions such as AEDK or AEDP. This profile follows PubChem rather than copying a sales page. A label saying “Cartalax” still does not prove that a vial contains AED. That is an identity question for analytical testing, not typography.

Cartalax belongs to the short-peptide family described in our bioregulator peptide guide. Related profiles include Vilon, Pinealon, and Epitalon, but evidence does not transfer between them merely because their names share a research tradition.

Does Cartalax repair cartilage or help joints?

Cartalax has not been shown to repair cartilage, reduce joint pain, or improve joint function in people. The marketing story usually runs like this: the sequence was associated with cartilage, so giving it back should restore cartilage. Origin and outcome are two different claims. Cartilage is not a return address.

The joint claim also leans on cell markers rather than repaired tissue. A 2023 review on peptides and chondrogenic stem-cell differentiation describes AED effects on gene expression in aging mesenchymal stem cells and markers in rat skin fibroblasts. The authors then suggest those data may indicate cartilage-repair properties because chondrocytes share features with fibroblasts. That is a biological hypothesis, not a cartilage experiment in a patient.

What does the Cartalax research actually show?

The strongest directly verified Cartalax-related finding is an in-vitro study of gene expression in aging human cell cultures. “Human cells” matters, but it does not make the experiment a human trial: nobody received Cartalax, and no joint outcome was measured.

In 2020, Ashapkin and colleagues tested AED, KED, and KE in aging human embryo bone-marrow mesenchymal stem cells. The PubMed-indexed paper reports that the peptides increased IGF1 gene expression across two cell-aging models and changed NF-kappa-B and other gene-expression measures. IGF1 is involved in growth and cell metabolism. More IGF1 messenger RNA in a dish does not establish new cartilage, pain relief, mobility, absorption, or a safe dose in a person.

The PubMed search for Cartalax does not surface a clinical trial of the named product. The honest verdict is therefore unknown, not “helped.” The experiment shows that cultured cells responded; it leaves the marketed joint claim unanswered.

What cartalax peptide benefits are established?

No cartalax peptide benefits are established in humans. Joint comfort, cartilage regeneration, faster injury recovery, and protection against osteoarthritis are marketing claims waiting for controlled clinical evidence. Cell-gene changes can help researchers choose what to test next, but they cannot supply a benefit size or tell how often a person would respond.

Cartalax still earns a place in the healing peptide reference because the question is real and the evidence distinction is useful. Readers comparing joint-repair options can also review BPC-157 and pentadeca-arginate. Those compounds have their own evidence records; none can lend Cartalax a result by association.

Is there a supported cartalax peptide dosage?

There is no evidence-based cartalax peptide dosage for people. No human pharmacokinetic study establishes absorption, half-life, route, dose response, or a tolerable range, and the cell-culture experiment used nanomolar concentrations rather than a clinical regimen.

Online schedules are therefore vendor or community protocols, not doses reported in a human Cartalax study. Converting a concentration placed directly onto cells into milligrams for an injection would manufacture precision. The sequence disagreement makes copied protocols even less useful: a dose cannot be interpreted cleanly when sellers may not agree on the molecule.

Is Cartalax safe, FDA-approved, or banned in sport?

Cartalax has no established human safety profile and is not FDA-approved for any use in the United States as of July 17, 2026. No trial has measured common adverse effects, uncommon harms, interactions, reproductive safety, immune reactions, or long-term outcomes. “No known side effects” would describe missing surveillance, not demonstrated safety.

The FDA explains that compounded drugs are not FDA-approved and are not reviewed before marketing for safety, effectiveness, or quality. A research-use-only label is not an FDA treatment indication. Product uncertainty adds practical risks involving identity, amount, purity, sterility, and endotoxin contamination.

Cartalax is not named individually on the 2026 WADA Prohibited List. WADA’s S0 category covers pharmacological substances without current approval for human therapeutic use. Because Cartalax lacks approval and its classification could be judged under that catch-all, a tested athlete should not read “not named” as “permitted.” The clinical research has not started yet; the sales certainty arrived first.